Sector News

Medtronic buys Crospon for endoscopic devices

December 12, 2017
Life sciences

Medtronic has bought endoscopic diagnostic player Crospon. The takeover, which media reports value at about $45 million, gives Medtronic control of FDA-cleared systems for assessing motility disorders and supporting the treatment of esophageal strictures.

Irish business publication Fora picked up on the news late last week, before the Times ran its own report on the takeover. Both publications put the value of the deal around the $45 million mark, although some of that figure is tied to milestones.

In return for the outlay, Medtronic is adding Endoflip and Esoflip to its portfolio.

Endoflip is built on functional luminal imaging probe (Flip) technology developed by Crospon. The device consists of a balloon catheter that is inserted into the area being measured and injected with a conductive solution. This enables electrodes in the balloon to record voltage. In doing so, Endoflip builds up a picture of the geometry of the esophagus, pylorus and anal sphincters using high-resolution impedance planimetry.

Crospon’s second device, Esoflip, works in conjunction with Endoflip to enable doctors to measure stricture size throughout the balloon dilation process without fluoroscopy.

Medtronic sees the devices slotting into its broader gastrointestinal portfolio.

“The acquisition expands our portfolio for the management of gastrointestinal diseases. With Crospon, Medtronic will have solutions to esophageal diseases from diagnosis to therapy,” a spokesperson for Medtronic told The Times.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

November 19, 2022

Sequana announces results from study of direct sodium removal

Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.

November 19, 2022

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

Life sciences

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

November 19, 2022

Pharma must stay the course on Twitter as docs are not abandoning the platform yet: Report

Life sciences

Like it or loathe it, and whatever its new direction, Twitter is still a powerful platform for doctors, and pharma should not abandon the troubled social media site yet, according to a new report from healthcare consultants at ZoomRx.